Current Clinical Pharmacology,volume 6,issue 3  (01-2011)

Period of time： 2011年3期

Publisher： Bentham Science Publishers

Founded in： 2006

Total resources： 44

E-ISSN： 2212-3938|6|3

ISSN： 1574-8847

Subject： R9 Pharmacy

Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Current Clinical Pharmacology,volume 6,issue 3

Menu

Editorial [Hot Topic: Kidney Cancer: State of the Art in 2011 (Guest Editor: Ulka Vaishampayan)]

Current Clinical Pharmacology,volume 6,issue 3 , Vol. 6, Iss. 3, 2011-08 , pp. 143-143

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma

Current Clinical Pharmacology,volume 6,issue 3 , Vol. 6, Iss. 3, 2011-08 , pp. 144-150

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Immunotherapy of Kidney Cancer

Current Clinical Pharmacology,volume 6,issue 3 , Vol. 6, Iss. 3, 2011-08 , pp. 151-163

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

VEGF Inhibitors in Metastatic Renal Cell Carcinoma: Current Therapies and Future Perspectives

Current Clinical Pharmacology,volume 6,issue 3 , Vol. 6, Iss. 3, 2011-08 , pp. 164-168

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Therapy for Non-Clear Cell Histologies in Renal Cancer

Current Clinical Pharmacology,volume 6,issue 3 , Vol. 6, Iss. 3, 2011-08 , pp. 169-180

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma

Current Clinical Pharmacology,volume 6,issue 3 , Vol. 6, Iss. 3, 2011-08 , pp. 181-188

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma

Current Clinical Pharmacology,volume 6,issue 3 , Vol. 6, Iss. 3, 2011-08 , pp. 189-198

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Looking Beyond Inhibition of VEGF/mTOR: Emerging Targets for Renal Cell Carcinoma Drug Development

Current Clinical Pharmacology,volume 6,issue 3 , Vol. 6, Iss. 3, 2011-08 , pp. 199-206

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Immunotherapy and Targeted Therapy Combinations in Renal Cancer

Current Clinical Pharmacology,volume 6,issue 3 , Vol. 6, Iss. 3, 2011-08 , pp. 207-213

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma

Current Clinical Pharmacology,volume 6,issue 3 , Vol. 6, Iss. 3, 2011-08 , pp. 214-221

Bentham Science Publishers

Abstract Access to resources Recommend Favorite

Total 10 item(s)